Advances in Circulating Tumor DNA Analysis.
Adv Clin Chem
; 80: 73-153, 2017.
Article
in En
| MEDLINE
| ID: mdl-28431643
ABSTRACT
The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might revolutionize cancer care with respect to early detection, identification of minimal residual disease, assessment of treatment response, and monitoring tumor evolution. ctDNA analysis, often referred to as "liquid biopsy" offers what tissue biopsies cannot-a continuous monitoring of tumor-specific changes during the entire course of the disease. Owing to technological improvements, efforts for the establishment of preanalytical and analytical benchmark, and the inclusion of ctDNA analyses in clinical trial, an actual clinical implementation has come within easy reach. In this chapter, recent advances of the analysis of ctDNA are summarized starting from the discovery of cell-free DNA, to methodological approaches and the clinical applicability.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
Type of study:
Prognostic_studies
/
Screening_studies
Limits:
Humans
Language:
En
Journal:
Adv Clin Chem
Year:
2017
Document type:
Article
Affiliation country:
Austria